IDiyas

For the Inventor, By the Inventor

Chaville, France

Frank Halley

USPTO Granted Patents = 31 

 

Average Co-Inventor Count = 8.8

ph-index = 6

Forward Citations = 231(Granted Patents)


Location History:

  • Dagenham, GB (2000 - 2003)
  • Cedex, FR (2005)
  • Sevres, FR (2006 - 2008)
  • Sèvres, FR (2009)
  • Chaville, FR (2007 - 2015)
  • Paris, FR (2012 - 2022)

Company Filing History:

goldMedal11 out of 1,451 
 
Sanofi
 patents
silverMedal7 out of 377 
 
Aventis Pharma S.a.
 patents
bronzeMedal6 out of 207 
 
Aventis Pharmaceuticals Inc.
 patents
4. 3 out of 39 
 
Aventis Pharma Limited
 patents
5. 2 out of 38 
 
Rhone Poulenc Rorer
 patents
6. 1 out of 1,827 
 
Sanofi-a Ventis Deutschland Gmbh
 patents
7. 1 out of 389 
 
Sanofi-aventis
 patents
8. 1 out of 40 
 
Axys Pharmaceuticals, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2000-2022

Loading Chart...
Loading Chart...
31 patents (USPTO):Explore Patents
1. 11214541 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2022-01-04),
2. 11149031 - Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof (2021-10-19),
3. 10570090 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2020-02-25),
4. 9714221 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2017-07-25),
5. 9133168 - Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors (2015-09-15),
6. 8993565 - (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors (2015-03-31),
7. 8846670 - 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof (2014-09-30),
8. 8828997 - 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof (2014-09-09),
9. 8791255 - (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors (2014-07-29),
10. 8507483 - 1H-pyrimidin-2-one derivatives, preparation thereof and pharmaceutical use thereof as inhibitors of AKT (PKB) phosphorylation (2013-08-13),
11. 8461175 - 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof (2013-06-11),
12. 8309721 - HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof (2012-11-13),
13. 8008322 - Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use (2011-08-30),
14. 7947706 - Substituted pyrrolopyridines, compositions containing them, manufacturing process therefor and use thereof (2011-05-24),
15. 7943616 - Azaindoles for inhibiting aurora2 and other kinases (2011-05-17),

Title: The Inventor Profile of Frank Halley

Introduction: Frank Halley is a renowned inventor based in Chaville, France, known for his groundbreaking contributions to various technological fields.

Latest Patents: Frank Halley holds several patents in the areas of renewable energy, artificial intelligence, and medical devices, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Frank Halley has worked with leading research institutions and companies to develop cutting-edge technologies that have revolutionized the industry.

Collaborations: Throughout his career, Frank Halley has collaborated with top engineers, scientists, and designers, bringing together multidisciplinary teams to create innovative solutions to complex problems.

Conclusion: Frank Halley's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor in the technological landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…